Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives

ABSTRACT

This invention relates to novel Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives of Formula (I): 
     
       
         
         
             
             
         
       
         
         
           
             and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R 1 , R 2 , R 3  R 4  and R 5  have meanings given in the description.

RELATED APPLICATIONS

The present application is a U.S. Non-Provisional Application whichclaims priority to U.S. Provisional Patent Application No. 62/035,577,filed Aug. 11, 2014, the entirety of which applications is herebyincorporated herein by reference.

FIELD OF THE INVENTION

This invention relates to novelPyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives and their use asTRPC5 modulators, pharmaceutical compositions containing the same, andmethods of using the same as agents for the treatment of TRPC5 receptormediated disorders or conditions.

BACKGROUND

A variety of ion channel proteins exist to mediate ion flux acrosscellular membranes. The proper expression and function of ion channelproteins is essential for the maintenance of cell function,intracellular communication, and the like. Numerous diseases are theresult of misregulation of membrane potential or aberrant calciumhandling. Given the central importance of ion channels in modulatingmembrane potential and ion flux in cells, identification of agents thatcan promote or inhibit particular ion channels are of great interest asresearch tools and as possible therapeutic agents.

Cation channels such as TRPC5 modulate the flux of calcium and sodiumions across cellular membranes. Sodium and calcium influx leads to adepolarization of the cell. This increases the probability thatvoltage-gated ion channels will reach the threshold required foractivation. As a result, activation of non-selective cation channels canincrease electrical excitability and increase the frequency ofvoltage-dependent events. Voltage-dependent events include, but are notlimited to, neuronal action potentials, cardiac action potentials,smooth muscle contraction, cardiac muscle contraction, and skeletalmuscle contraction.

Calcium influx caused by the activation of non-selective cation channelssuch as TRPC5 also alters the intracellular free calcium concentration.Calcium is a ubiquitous second messenger molecule within the cell andthe alterations in intracellular calcium levels have profound effects onsignal transduction and gene expression. Thus, activation ofnon-selective cation channels such as TRPC5 can lead to changes in geneexpression and cellular phenotype. Gene expression events include, butare not limited to, production of mRNAs encoding cell surface receptors,ion channels, and kinases. These changes in gene expression can lead tohyperexcitability in that cell.

Transient receptor potential (TRP) homomeric TRPC5 ion channels aresignal transduction gated, Ca²⁺-permeable channels predominantlyexpressed in the neurons. TRPC5 forms homomultimeric structures such astetramers (i.e., TRPC5 homomultimers) and heteromultimeric structuressuch as tetramers (i.e., TRPC5-TRPC1 heteromultimers). Unless expresslystated otherwise, when the term TRPC5 is used herein, for example, whenidentifying a modulator of TRPC5 such as a TRPC5 antagonist, the termTRPC5 is used generically so as to include either or both of a TRPC5homomultimer or a heteromultimer (e.g., TRPC5-TPRC1 or TRPC5-TRPC4heteromultimer). Examples of TRPC5 in the literature include thefollowing: Nature. 2008 Jan. 3; 451 (7174):69-72; Mol Pharmacol. 2008January; 73 (1):42-9; J Biol Chem. 2007 Nov. 16; 282 (46):33868-78;Biochem Biophys Res Commun. 2008 Jan. 11; 365 (2):239-45; J Biol Chem.2006 Nov. 3; 281 (44):33487-96; Eur J Pharmacol. 2005 Mar. 14; 510(3):217-22; J Biol Chem. 2006 Feb. 24; 281 (8):4977-82; Biochem SocTrans. 2007 February; 35 (Pt 1):101-4; Handb Exp Pharmacol. 2007;(179):109-23; J Biol Chem. 2005 Mar. 25; 280 (12):10997-1006; J Physiol.2006 Jan. 15; 570 (Pt 2):219-35; and Nat Neurosci. (2003) 6: 837-45.

Modulating the function of TRPC5 proteins provides a means of modulatingcalcium homeostasis, sodium homeostasis, membrane polarization, and/orintracellular calcium levels, and compounds that can modulate TRPC5function are useful in many aspects, including, but not limited to,maintaining calcium homeostasis, modulating intracellular calciumlevels, modulating membrane polarization, and treating or preventingdiseases, disorders, or conditions associated with calcium and/or sodiumhomeostasis or dyshomeostasis.

SUMMARY OF THE INVENTION

The present invention provides compounds of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein constituentmembers are provided herein.

The present invention further provides compositions comprising acompound of Formula (I) and a pharmaceutically acceptable excipient,diluent or carrier.

The present invention further provides methods of treating a TRPC5mediated disorder in a subject, e.g. a human subject, comprisingadministering to the subject a compound or composition of a compound ofFormula (I) or a pharmaceutically acceptable salt thereof, to therebytreat the subject, e.g., a human subject.

The present invention provides methods and compositions for treatingconditions such as a neuropsychiatric disorder, a neurodegenerativedisorder, nephropathy, and seizure disorder by modulating the activityof the transient receptor potential cation channel subfamily C, member 5(TRPC5), which can exist in homomultimeric form as well asheteromultimeric form with other ion channels such as TRPC1 or TRPC3(i.e., TRPC5-TRPC1 and TRPC1-TRPC3-TRPC5). The compound of Formula (I)modulate the function of TRPC5 by inhibiting a TRPC5-mediated ion fluxor by inhibiting the inward current, the outward current, or bothcurrents mediated by TRPC5. The inhibition of a particular current isthe ability to inhibit or reduce such current (e.g., inward and/oroutward) in an in vitro or an in vivo assay. The activation of aparticular current is the ability to activate or increase such current(e.g., inward and/or outward) in an in vitro or an in vivo assay.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is C₂-C₁₀ hydroxyalkyl, optionally substituted with 1-3 R⁵;

R² is H, C₁-C₆ alkyl, C₂-C₆ hydroxyalkyl, cycloalkyl, C₂-C₆ alkenyl,C₂-C₆ alkynyl, or C₁-C₆ alkoxy;

R³ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆acyl, C₃-C₁₀ cycloalkyl, halo, hydroxyl, C₆-C₁₂ aryl, 5-14-memberedheteroaryl, 3-18-membered heterocycloalkyl, amino, C₁-C₆ alkylamino,C₂-C₁₂ dialkylamino, —C(O)NH—, —C(O)N—C₁-C₆ alkyl-, —NHC(O)—, —N— C₁-C₆alkyl C(O)—, urea, sulfonylurea, nitro, or cyano each of which isoptionally substituted with 1-4 R⁶;

R⁴ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ acyl, C₁-C₆alkoxy, C₄-C₁₀ cycloalkyloxy, halo, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy,hydroxyl, alkylthio, sulfonamidyl, C₆-C₁₂ aryl, 5-14-memberedheteroaryl, C₆-C₁₂ aryl-C₁-C₆ alkyl, 5-14-membered heteroaryl-C₁-C₆alkyl, C₆-C₁₂ aryloxy, —O—C₆-C₁₂ aryl-C₁-C₆ alkyl, —O— C₁-C₆alkyl-C₆-C₁₂ aryl, —C₆-C₁₂ aryl-C₁-C₆ alky-O, 5-14-memberedheteroaryloxy, 3-18-membered heterocycloalkyl, amino, C₁-C₆ alkylamino,C₂-C₁₂ dialkylamino, —C(O)NH—, —C(O)N—C₁-C₆ alkyl-, —NHC(O)—, —N— C₁-C₆alkyl C(O)—, urea, sulfonylurea, nitro, or cyano, each of which isoptionally substituted with 1-4 R⁷;

R⁵ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ acyl, C₁-C₆alkoxy, C₄-C₁₀ cycloalkyloxy, halo, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy,hydroxyl, alkylthio, sulfonamidyl, C₆-C₁₂ aryl, 5-14-memberedheteroaryl, C₆-C₁₂ aryl-C₁-C₆ alkyl, 5-14-membered heteroaryl-C₁-C₆alkyl, C₆-C₁₂ aryloxy, —O—C₆-C₁₂ aryl-C₁-C₆ alkyl, —O—C₁-C₆ alkyl-C₆-C₁₂aryl, —C₆-C₁₂ aryl-C₁-C₆ alky-O, 5-14-membered heteroaryloxy,3-18-membered heterocycloalkyl, amino, C₁-C₆ alkylamino, C₂-C₁₂dialkylamino, —C(O)NH—, —C(O)N—C₁-C₆ alkyl-, —NHC(O)—, —N— C₁-C₆ alkylC(O)—, urea, sulfonylurea, nitro, or cyano, each of which is optionallysubstituted with 1-4 R⁷;

wherein at least two of R³, R⁴ and R⁵ are not H;

each R⁶ is independently C₁-C₃ alkyl, halo, hydroxyl, or amino; and

each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,C₁-C₆ acyl, halo, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, hydroxyl, aryl,heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, cycloalkyloxy, aryloxy,arylalkoxy, heteroaryloxy, amino, C₁-C₆ alkylamino, C₂-C₁₂ dialkylamino,—C(O)NH—, —C(O)N—C₁-C₆ alkyl-, —NHC(O)—, —N— C₁-C₆ alkyl C(O)—, nitro,or cyano.

In a second embodiment, in the general formula I, R², R³, R⁴, R⁵, R⁶,and R⁷ have the same meaning as defined in the preceding embodiments,and R¹ is 3-hydroxypropyl; or a pharmaceutically acceptable saltthereof.

In another embodiment, in the general formula I, R¹, R³, R⁴, R⁵, R⁶, andR⁷ have the same meaning as defined in any of the preceding embodiments,and R² is C₁-C₄ alkyl.

In another embodiment, in the general formula I, R¹, R³, R⁴, R⁵, R⁶, andR⁷ have the same meaning as defined in any of the preceding embodiments,and R² is methyl.

In another embodiment, in the general formula I, R¹, R², R⁴, and R⁵ havethe same meaning as defined in any of the preceding embodiments, and R³is H, C₁-C₄ alkyl, or phenyl, the latter group optionally substitutedwith one or more halogens.

In another embodiment, in the general formula I, R¹, R², R⁴, and R⁵ havethe same meaning as defined in any of the preceding embodiments, and R³is methyl or 3-chlorophenyl.

In another embodiment, in the general formula I, R¹, R², R³, and R⁵ havethe same meaning as defined in any of the preceding embodiments, and R⁴is H, C₁-C₄ alkyl, or phenyl, the latter group substituted with one ormore halogens or —OCF₃.

In another embodiment, in the general formula I, R¹, R², R³, and R⁵ havethe same meaning as defined in any of the preceding embodiments, and R⁴is 3-chlorophenyl or 3-trifluoromethoxyphenyl.

In another embodiment, in the general formula I, R¹, R², R³, and R⁴ havethe same meaning as defined in any of the preceding embodiments, and R⁵is H, C₁-C₄ alkyl, or benzyl, the latter group substituted with one ormore halogens.

In another embodiment, in the general formula I, R¹, R², R³, and R⁴ havethe same meaning as defined in any of the preceding embodiments, and R⁵is methyl or 4-chlorobenzyl.

A further embodiment of the present invention comprises compounds offormula I in which:

R¹ is 3-hydroxypropyl;

R² is methyl;

R³ is H, methyl or 3-chlorophenyl;

R⁴ is H, 3-chlorophenyl or 3-trifluoromethoxyphenyl; and

R⁵ is H, methyl or 4-chlorobenzyl;

or a pharmaceutically acceptable salt thereof.

In certain embodiments, exemplary compounds of Formula (I) include thecompounds described in Table 1 and in the Examples.

TABLE 1 Com- pound Number Structure 29

30

32

33

34

35

36

37

The present invention further provides compositions comprising acompound of Formula (I) and a pharmaceutically acceptable carrier.

The present invention further provides methods of treating a TRPC5mediated disorder in a subject, e.g. a human subject, comprisingadministering to the subject a compound or composition of a compound ofFormula (I) or a pharmaceutically acceptable salt thereof, to therebytreat the subject, e.g., a human subject.

The present invention provides methods and compositions for treatingconditions such as a neuropsychiatric disorder, a neurodegenerativedisorder, nephropathy, and seizure disorder by modulating the activityof the transient receptor potential cation channel subfamily C, member 5(TRPC5), which can exist in homomultimeric form as well asheteromultimeric form with other ion channels such as TRPC1 or TRPC3(i.e., TRPC5-TRPC1 and TRPC1-TRPC3-TRPC5). The compound of Formula (I)modulate the function of TRPC5 by inhibiting a TRPC5-mediated ion fluxor by inhibiting the inward current, the outward current, or bothcurrents mediated by TRPC5. The inhibition of a particular current isthe ability to inhibit or reduce such current (e.g., inward and/oroutward) in an in vitro or an in vivo assay. The activation of aparticular current is the ability to activate or increase such current(e.g., inward and/or outward) in an in vitro or an in vivo assay.

In one aspect, the invention relates to a method for treating acondition for which reduced TRPC5 activity can reduce the severity ofthe condition, by administering a TRPC5 antagonist, such as a compoundof Formula (I), that inhibits TRPC5-mediated current and/orTRPC5-mediated ion flux. Described in greater detail herein arecompounds of Formula (I), which are TRPC5 antagonists that have ameasured IC₅₀ for inhibition of TRPC5 of 10 nanomolar or less. Incertain embodiments, the compounds of Formula (I), which are TRPC5antagonists inhibit one or both of inward and outward TRPC5-mediatedcurrents with an IC₅₀ 10 nanomolar or less. In certain embodiments, thecompounds of Formula (I) inhibit at least 95% of TRPC5-mediated currentor TRPC5-mediated ion flux when administered at 1 micromolar or less.

In another aspect, compounds of Formula (I), which are TRPC5antagonists, can be used to inhibit a function of TRPC5, for example aTRPC5-mediated current and/or a TRPC5-mediated ion flux. In someembodiments, compounds of Formula (I) can be used to inhibit a TRPC5mediated current in vitro, for example in cells in culture. In otherembodiments, compounds of Formula (I) can be used to inhibit a TRPC5mediated current in vivo. In certain embodiments, compounds of Formula(I) inhibit both an inward and an outward TRPC5-mediated current.

Another aspect of the invention features a pharmaceutical preparationsuitable for use in a human patient, or for veterinary use, comprisingan effective amount of a compound of Formula (I) (or a salt thereof, ora solvate, hydrate, oxidative metabolite or prodrug of the compound orits salt), and one or more pharmaceutically acceptable excipients,diluents, or carriers. The invention further contemplates the use ofcompounds of Formula (I) in the manufacture of a medicament orpharmaceutical preparation to treat or reduce the symptoms of any of thediseases or conditions provided in the specification. The compounds ofFormula (I) for use in treating a particular disease or condition can beformulated for administration via a route appropriate for the particulardisease or condition.

Compounds of Formula (I) can be administered alone or in combinationwith another therapeutic agent. For instance, the compounds of Formula(I) can be administered conjointly with one or more of ananti-inflammatory agent, anti-acne agent, anti-wrinkle agent,anti-scarring agent, anti-psoriatic agent, anti-proliferative agent,anti-fungal agent, anti-viral agent, anti-septic agent, anti-migraineagent, keratolytic agent, or a hair growth inhibitor.

Compounds of Formula (I) can be administered topically, orally,transdermally, rectally, vaginally, parentally, intranasally,intrapulmonary, intraocularly, intravenously, intramuscularly,intraarterially, intrathecally, intracapsularly, intraorbitally,intracardiacly, intradermally, intraperitoneally, transtracheally,subcutaneously, subcuticularly, intraarticularly, subcapsularly,subarachnoidly, intraspinally, intrasternally, sublingually, or byinhalation.

In some embodiments, compounds of Formula (I) can be administeredtopically.

In some embodiments, compounds of Formula (I) can be administeredorally.

In some embodiments, compounds of Formula (I) can be administeredparentally.

DEFINITIONS

At various places in the present specification, substituents ofcompounds of the invention are disclosed in groups or in ranges. It isspecifically intended that the invention include each and everyindividual subcombination of the members of such groups and ranges. Forexample, the term “C₁₋₆ alkyl” is specifically intended to individuallydisclose methyl, ethyl, C₃ alkyl, C₄ alkyl, C₅ alkyl, and C₆ alkyl.

For compounds of the invention in which a variable appears more thanonce, each variable can be a different moiety selected from the Markushgroup defining the variable. For example, where a structure is describedhaving two R groups that are simultaneously present on the samecompound; the two R groups can represent different moieties selectedfrom the Markush group defined for R.

It is further appreciated that certain features of the invention, whichare, for clarity, described in the context of separate embodiments, canalso be provided in combination in a single embodiment. Conversely,various features of the invention which are, for brevity, described inthe context of a single embodiment, can also be provided separately orin any suitable subcombination. Compounds may be depicted by bothchemical name and structure and in the event of conflict between the twothe structure controls.

As used herein, “acyl” refers to the group (C₁-C₆ alkyl)-C(O)—.

As used herein, “alkyl,” by itself or as part of another substituent,means, unless otherwise stated, a straight or branched chain, and canhave a number of carbon atoms optionally designated (i.e., C₁-C₆ meansone to six carbons). Examples of saturated hydrocarbon groups include,but are not limited to, groups such as methyl, ethyl, n-propyl,isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, isopentyl,homologs and isomers of, for example, n-pentyl, n-hexyl, and the like.

As used herein, “alkenyl” can be a straight or branched hydrocarbonchain, containing at least one double bond, and having from two to sixcarbon atoms (i.e., C₂-C₆ alkenyl). Examples of alkenyl groups, include,but are not limited to, groups such as ethenyl (i.e., vinyl),prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl,and the like.

As used herein, “alkynyl” can be a straight or branched hydrocarbonchain, containing at least one triple bond, having from two to sixcarbon atoms (i.e., C₂-C₆ alkynyl). Examples of alkynyl groups, include,but are not limited to, groups such as ethynyl, propynyl, butynyl,pentynyl, hexynyl, and the like.

As used herein, “alkoxy” can be a straight chain or branched alkoxygroup having from one to six carbon atoms (i.e., C₁-C₆ alkoxy). Examplesof alkoxy groups, include, but are not limited to, groups such asmethoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy,tert-butyloxy, pentyloxy, or hexyloxy, and the like.

As used herein, “amide” or “amido” refers to a chemical moiety with theformula —C(O)NR^(a)— or —NR^(a)C(O)— wherein R^(a) is H or C₁-C₆ alkyl.

As used herein, “amino” or “amine” refers to a —NH₂ radical group.

As used herein, “alkylamino” refers to a group of formula —NH(alkyl),wherein the alkyl group each has 1 to 6 carbons.

As used herein, the term “dialkylamino” refers to a group of formula—N(alkyl)₂, wherein the two alkyl groups each independently have 1 to 6carbons.

As used herein, “aryl” refers to a polyunsaturated, aromatic,hydrocarbon moiety which can be a single ring or multiple rings (e.g., 1to 2 rings) which are fused together or linked covalently, having fromsix to twelve carbon atoms (i.e., C₆-C₁₂ aryl). Non-limiting examples ofaryl groups include phenyl, 1-naphthyl, 2-naphthyl, and 4-biphenyl.

As used herein, “arylalkyl” refers to an (aryl)alkyl-radical whereinaryl and alkyl moieties are as disclosed herein. The arylalkyl may berepresented as C₆-C₁₂ aryl-C₁-C₆ alkyl, a phenylalkyl, e.g. benzyl, andas structures such as the following non-limiting exemplary structures:

As used herein, “aryloxy” refers to —O-(aryl), wherein the aryl moietyis as defined herein. In one-non-limiting example, the may be phenoxyincluding the following exemplary structure.

As used herein, “arylalkoxy” refers to —O-(arylalkyl), wherein thearylalkyl moiety is as defined herein e.g. —O—C₆-C₁₂ aryl-C₁-C₆ alkyl,—O— C₁-C₆ alkyl-C₆-C₁₂ aryl, and C₆-C₁₂ aryl-C₁-C₆ alky-O.

As used herein, “carboxyl” refers to a —(C═O) radical.

As used herein, “cyano” refers to a —CN radical.

As used herein, “cycloalkyl” refers to a monocyclic or polycyclicradical that contains only carbon and hydrogen, and may be saturated, orpartially unsaturated. Cycloalkyl groups include groups having from 3 to10 ring atoms (i.e. C₃-C₁₀ cycloalkyl). Examples of cycloalkyl groupsinclude, but are not limited to, groups such as cyclopropyl, cyclobutyl,cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloseptyl,cyclooctyl, cyclononyl, cyclodecyl, norbornyl, and the like.

As used herein, “cycloalkyloxy” refers to —O-(cycloalkyl), wherein thecycloalkyl moiety is as defined herein e.g. —O—(C₃-C₁₀ cycloalkyl).

As used herein, “halo” or “halogen,” independently or as part of anothersubstituent, mean, unless otherwise stated, a fluorine, chlorine,bromine, or iodine atom. The term “halide” by itself or as part ofanother substituent, refers to a fluoride, chloride, bromide, or iodideatom.

As used herein, “haloalkyl” and “haloalkoxy” can include alkyl andalkoxy structures that are substituted with one or more halo groups orwith combinations thereof. For example, the terms “fluoroalkyl” and“fluoroalkoxy” include haloalkyl and haloalkoxy groups, respectively, inwhich the halo is fluorine.

As used herein, “heteroaryl” refers to a 5- to 14-membered aromaticradical (e.g., C₂-C₁₃ heteroaryl) that includes one or more ringheteroatoms selected from nitrogen, oxygen and sulfur, and which may bea monocyclic or bicyclic ring system. Bivalent radicals derived fromunivalent heteroaryl radicals whose names end in “-yl” by removal of onehydrogen atom from the atom with the free valence are named by adding“-idene” to the name of the corresponding univalent radical, e.g., apyridyl group with two points of attachment is a pyridylidene. AnN-containing “heteroaromatic” or “heteroaryl” moiety refers to anaromatic group in which at least one of the skeletal atoms of the ringis a nitrogen atom. The polycyclic heteroaryl group may be fused ornon-fused. The heteroatom(s) in the heteroaryl radical is optionallyoxidized. One or more nitrogen atoms, if present, are optionallyquaternized. The heteroaryl is attached to the rest of the moleculethrough any atom of the ring(s). Examples of heteroaryl groups includewithout limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl,triazinyl, furyl (furanyl), quinolyl, isoquinolyl, thienyl, imidazolyl,thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl,benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl,1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl,benzimidazolyl, indolinyl, and the like.

As used herein, “heteroarylalkyl” refers to refers to an(heteroaryl)alkyl-radical wherein the heteroaryl and alkyl moieties areas disclosed herein. A heteroarylalkyl may be represented as5-14-membered heteroaryl-C₁-C₆ alkyl, by name such as a pyridylalkyl andmay be depicted as a structure as in the following non-limitingstructural example

As used herein, “heteraryloxy” refers to —O-(heteroaryl), wherein theheteroaryl moiety is as defined herein. For example, such heteraryloxymay include a pyridyloxy as depicted in the following structural example

As used herein, “heterocycloalkyl” can be a stable 3- to 18-memberednon-aromatic ring radical that comprises two to twelve carbon atoms andfrom one to six heteroatoms selected from nitrogen, oxygen and sulfur.Examples of heterocycloalkyl groups include, but are not limited to,groups such as dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl,imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl,morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl,2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl,piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl,thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl,1,1-dioxo-thiomorpholinyl, and the like.

As used herein, “hydroxy” or “hydroxyl” refers to —OH.

As used herein, “hydroxyalkyl” refers to an alkyl group having 1 to 10carbon atoms, which is substituted with a hydroxyl group, e.g.,hydroxypropyl.

As used herein, “keto” refers to a ═O radical.

As used herein, “nitro” refers to —NO₂.

As used herein, “urea” refers to —NR^(a)—C(O)—NR^(a) ₂ or—NR^(a)—C(O)NR^(a)—, wherein R^(a) is H or C₁-C₆ alkyl.

As used herein, “sulfonyl” refers to —S(O)₂—R^(a), wherein R^(a) isC₁-C₆ alkyl.

As used herein, “sulfonylurea” refers to —S(O)₂—NR^(a)—C(O)—NR^(a)— or—NR^(a)—C(O)—NR^(a)—SO₂—, wherein R^(a) is H or C₁-C₆ alkyl.

As used herein, “sulfonamidyl” refers to —S(O)₂—NR^(a)— or—NR^(a)—S(O)₂—, wherein R^(a) is H or C₁-C₆ alkyl.

As used herein, “thionyl” refers to —S(O)—R^(a), wherein R^(a) is C₁-C₆alkyl.

The terms “antagonist” and “inhibitor” are used interchangeably to referto an agent that decreases or suppresses a biological activity, such asto repress an activity of an ion channel, such as TRPC5. TRPC5 ionchannels as described herein include homomultimeric and heteromultimericstructures (e.g., homomultimeric TRPC5 and heteromeric TRPC5-TRPC1 orTRPC5-TRPC4). TRPC5 antagonists include inhibitors having anycombination of the structural and/or functional properties disclosedherein.

An “effective amount” of, e.g., a TRPC5 antagonist, with respect to thesubject methods of inhibition or treatment, refers to an amount of theantagonist in a preparation which, when applied as part of a desireddosage regimen brings about a desired clinical or functional result.Without being bound by theory, an effective amount of a TRPC5 antagonistfor use in the methods of the present invention includes an amount of aTRPC5 antagonist effective to decrease one or more in vitro or in vivofunction of a TRPC5 channel. Exemplary functions include, but are notlimited to, membrane polarization (e.g., an antagonist may promotehyperpolarization of a cell), ion flux, ion concentration in a cell,outward current, and inward current. Compounds that antagonize TRPC5function include compounds that antagonize an in vitro or in vivofunctional activity of TRPC5. When a particular functional activity isonly readily observable in an in vitro assay, the ability of a compoundto inhibit TRPC5 function in that in vitro assay serves as a reasonableproxy for the activity of that compound. In certain embodiments, aneffective amount is an amount sufficient to inhibit a TRPC5-mediatedcurrent and/or the amount sufficient to inhibit TRPC5 mediated ion flux.

The TRPC5 antagonists for use in the methods of the present inventionmay be characterized according to their activity, or lack of activity,against one or more other ion channels. When other ion channels arereferred to, inhibition of a function of such other ion channels isdefined similarly. For example, inhibition of an ion channel or anactivity of an ion channel means the antagonist inhibits one or morefunctional activities of the other ion channel. Such functions includethe current mediated by the particular ion channel, ion flux, ormembrane polarization.

The term “preventing” is art-recognized, and when used in relation to acondition, such as a local recurrence, a disease such as cancer, asyndrome complex such as heart failure or any other medical condition,is well understood in the art, and includes administration of acomposition which reduces the frequency of, or delays the onset of,symptoms of a medical condition in a subject relative to a subject whichdoes not receive the composition. Thus, prevention of cancer includes,for example, reducing the number of detectable cancerous growths in apopulation of patients receiving a prophylactic treatment relative to anuntreated control population, and/or delaying the appearance ofdetectable cancerous growths in a treated population versus an untreatedcontrol population, e.g., by a statistically and/or clinicallysignificant amount. Prevention of an infection includes, for example,reducing the number of diagnoses of the infection in a treatedpopulation versus an untreated control population, and/or delaying theonset of symptoms of the infection in a treated population versus anuntreated control population. Prevention of pain includes, for example,reducing the magnitude of, or alternatively delaying, pain sensationsexperienced by subjects in a treated population versus an untreatedcontrol population.

The term “small molecule” refers to a compound having a molecular weightless than about 2500 amu, preferably less than about 2000 amu, even morepreferably less than about 1500 amu, still more preferably less thanabout 1000 amu, or most preferably less than about 750 amu.

The terms “TRPC5”, “TRPC5 protein”, and “TRPC5 channel” are usedinterchangeably throughout the application. Unless expressly stated, theterm TRPC5 includes homomultimeric structures (e.g., homomultimericTRPC5) and heteromultimeric structures (e.g., heteromultimericTRPC5-TRPC1).

The term “oxidative metabolite” is intended to encompass compounds thatare produced by metabolism of the parent compound under normalphysiological conditions. Specifically, an oxidative metabolite isformed by oxidation of the parent compound during metabolism. Forexample, a thioether group may be oxidized to the correspondingsulfoxide or sulfone.

The term “solvate” as used herein, refers to a compound formed bysolvation (e.g., a compound formed by the combination of solventmolecules with molecules or ions of the solute).

The term “hydrate” as used herein, refers to a compound formed by theunion of water with the parent compound.

The term “treating” includes prophylactic and/or therapeutic treatments.The term “prophylactic or therapeutic” treatment is art-recognized andincludes administration to the host of one or more of the subjectcompositions. If it is administered prior to clinical manifestation ofthe unwanted condition (e.g., disease or other unwanted state of thehost animal) then the treatment is prophylactic, (i.e., it protects thehost against developing the unwanted condition), whereas if it isadministered after manifestation of the unwanted condition, thetreatment is therapeutic, (i.e., it is intended to diminish, ameliorate,or stabilize the existing unwanted condition or side effects thereof).

Contemplated equivalents of the compounds described above includecompounds which otherwise correspond thereto, and which have the samegeneral properties thereof (e.g., the ability to antagonize TRPC5activity), wherein one or more simple variations of substituents aremade which do not adversely affect the efficacy of the compound. Ingeneral, the compound of the present invention may be prepared by themethods illustrated in the general reaction schemes as, for example,described below, or by modifications thereof, using readily availablestarting materials, reagents and conventional synthesis procedures. Inthese reactions, it is also possible to make use of variants which arein themselves known, but are not mentioned here.

For purposes of this invention, the chemical elements are identified inaccordance with the Periodic Table of the Elements, CAS version,Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover. Alsofor purposes of this invention, the term “hydrocarbon” is contemplatedto include all permissible compounds having at least one hydrogen andone carbon atom. In a broad aspect, the permissible hydrocarbons includeacyclic and cyclic, branched and unbranched, carbocyclic andheterocyclic, aromatic and nonaromatic organic compounds which can besubstituted or unsubstituted.

The compounds described herein can be asymmetric (e.g., having one ormore stereocenters). All stereoisomers, such as enantiomers anddiastereomers, are intended unless otherwise indicated. Compounds of thepresent invention that contain asymmetrically substituted carbon atomscan be isolated in optically active or racemic forms. Methods on how toprepare optically active forms from optically active starting materialsare known in the art, such as by resolution of racemic mixtures or bystereoselective synthesis. Many geometric isomers of olefins, C═N doublebonds, and the like can also be present in the compounds describedherein, and all such stable isomers are contemplated in the presentinvention. Cis and trans geometric isomers of the compounds of thepresent invention are described and may be isolated as a mixture ofisomers or as separated isomeric forms.

Resolution of racemic mixtures of compounds can be carried out by any ofnumerous methods known in the art. An example method includes fractionalrecrystallizaion using a “chiral resolving acid” which is an opticallyactive, salt-forming organic acid. Suitable resolving agents forfractional recrystallization methods are, for example, optically activeacids, such as the D and L forms of tartaric acid, diacetyltartaricacid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid orthe various optically active camphorsulfonic acids such asβ-camphorsulfonic acid. Other resolving agents suitable for fractionalcrystallization methods include stereoisomerically pure forms ofα-methylbenzylamine (e.g., S and R forms, or diastereomerically pureforms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine,cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.

Resolution of racemic mixtures can also be carried out by elution on acolumn packed with an optically active resolving agent (e.g.,dinitrobenzoylphenylglycine). Suitable elution solvent composition canbe determined by one skilled in the art. Compounds of the invention alsoinclude tautomeric forms, such as keto-enol tautomers.

Compounds of the invention can exist in unsolvated forms as well assolvated forms, including hydrated forms. In general, the solvated formsare equivalent to unsolvated forms and are encompassed within the scopeof the present invention.

The term “pharmaceutically acceptable salts” includes salts of acompound of formula (I) which are prepared with relatively nontoxicacids or bases. Base addition salts can be obtained by contacting theneutral form of a compound of formula (I) with a sufficient amount ofthe desired base, either neat or in a suitable inert solvent. Examplesof pharmaceutically acceptable base addition salts include sodium,potassium, calcium, ammonium, organic amino, or magnesium salt, or asimilar salt. Acid addition salts can be obtained by contacting theneutral form of a compound of formula (I) with a sufficient amount ofthe desired acid, either neat or in a suitable inert solvent. Examplesof pharmaceutically acceptable acid addition salts include those derivedfrom inorganic acids like hydrochloric, hydrobromic, nitric, carbonic,monohydrogencarbonic, phosphoric, monohydrogenphosphoric,dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, orphosphorous acids and the like, as well as the salts derived fromrelatively nontoxic organic acids like acetic, trifluoroacetic,propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic,fumaric, lactic, mandelic, phthalic, benzensulfonic, p-tolylsulfonic,citric, tartaric, methanesulfonic, and the like. Also included are thesalts of amino acids such as arginate and the like, and salts of organicacids like glucuronic or galactunoric acids and the like (see, forexample, Berge et al., “Pharmaceutical Salts”, Journal of PharmaceuticalScience, 1977, 66, 1-19).

The neutral forms of a compound of Formula (I) is preferably regeneratedby contacting the salt with a base or acid and isolating the parentcompound in the conventional manner. The parent form of the compounddiffers from the various salt forms in certain physical properties, suchas solubility in polar solvents, but otherwise the salts are equivalentto the parent form of the compound for the purposes of the presentinvention.

The term “low enough pyrogen activity”, with reference to apharmaceutical preparation, refers to a preparation that does notcontain a pyrogen in an amount that would lead to an adverse effect(e.g., irritation, fever, inflammation, diarrhea, respiratory distress,endotoxic shock, etc.) in a subject to which the preparation has beenadministered. For example, the term is meant to encompass preparationsthat are free of, or substantially free of, an endotoxin such as, forexample, a lipopolysaccharide (LPS).

Diseases, Disorders, or Conditions Related to TRPC5 Function

In certain embodiments, the invention provides methods and compositionsfor antagonizing a function of a TRPC5 channel in vitro or in vivo.Exemplary functions include, but are not limited to, TRPC5-mediatedcurrent. In certain embodiments, the invention provides methods fortreating a disease or disorder or condition by administering a compoundof the invention. In other embodiments, the compound as described hereinselectively inhibits the expression level and/or activity of a TRPC5protein. In other words, in certain embodiment, the compound asdescribed herein inhibits the activity of a TRPC5 protein preferentiallyin comparison to the activity of one or more other ion channels.

Treatment of Anxiety and Fear-Related Disorders

In certain embodiments, the compounds of the invention can be used forpreventing or treating anxiety and fear-related disorders (see, e.g.,Riccio et al. (2009) Cell 137:761-72). Examples of such disordersinclude post-traumatic stress disorder, panic disorder, agoraphobia,social phobias, generalized anxiety disorder, panic disorder, socialanxiety disorder, obsessive-compulsive disorder, and separation anxiety.

Memory, Motion and Mood Disorders

A compound of Formula (I) is also useful for the treatment ofParkinson's disease, epilepsy, memory disorders, stroke, seizure, andmood disorders. Mood disorders include depression (e.g., majordepression, psychiatric depression, dysthymia, and postpartumdepression) and bipolar disorder (e.g., bipolar I, bipolar II, andcyclothymia). Memory disorders are conditions associated with any memoryloss and may result from Alzheimer's disease, amnesia, aphasia,atherosclerosis, brain injury or disorder, brain tumor, chronic fatiguesyndrome, Creutzfedt-Jacob disease, dissociative amnesia, depression,fuge amnesia, Huntington's disease, learning disorders, sleepingdisorders, multiple personality disorder, pain, post-traumatic stressdisorder, schizophrenia, sports injuries, stroke, and Wernicke-Korsakoffsyndrome.

Treatment of Pain, Sensitivity to Pain and Touch, or Pain-RelatedDiseases or Disorders

In certain embodiments, a compound of Formula (I) is used to treat orameliorate pain. Exemplary classes of pain that can be treated using acompound of Formula (I) include, but are not limited to nociceptivepain, inflammatory pain, and neuropathic pain. The pain can be chronicor acute.

A compound of Formula (I) may be particularly useful in the treatment ofpain associated with cancer, osteoarthritis, rheumatoid arthritis,post-herpetic neuralgia, burns, and other indications detailed above. Tofurther illustrate, additional exemplary indications for which acompound of Formula (I) can be used include oral pain, pelvic pain,Fabry's disease, complex regional pain syndrome, pancreatitis, andfibromyalgia syndrome.

A compound of Formula (I) may also be used in connection with preventionor treatment of sensitivity to pain and touch. Pain or sensitivity topain and touch may be indicated in a variety of diseases, disorders orconditions, including, but not limited to, diabetic neuropathy, breastpain, psoriasis, eczema, dermatitis, burn, post-herpetic neuralgia(shingles), nociceptive pain, peripheral neuropathic and centralneuropathic pain, chronic pain, cancer and tumor pain, spinal cordinjury, crush injury and trauma induced pain, migraine, cerebrovascularand vascular pain, sickle cell disease pain, rheumatoid arthritis pain,musculoskeletal pain including treating signs and symptoms ofosteoarthritis and rheumatoid arthritis, orofacial and facial pain,including dental, temperomandibular disorder, and cancer related, lowerback or pelvic pain, surgical incision related pain, inflammatory andnon-inflammatory pain, visceral pain, psychogenic pain and soft tissueinflammatory pain, fibromyalgia-related pain, and reflex sympatheticdystrophy, and pain resulting from kidney stones or urinary tractinfection.

The foregoing are merely exemplary of diseases and conditions that causeor lead to inflammation, lesions, ulcers, or other sources of oral pain.In other embodiments, the oral pain is due to an injury to the mouth,jaw, lips, gums, or teeth. In other embodiments, the oral pain is due tooral surgery, for example, surgery for cancer, tooth extraction, or jawremodeling. Other conditions that may lead to oral ulcers, and thus oralpain, include, but are not limited to chickpox, herpes zoster,infectious mononucleosis, syphilis, tuberculosis, acute necrotizinggingivitis, and burning mouth syndrome.

Fibromyalgia (FMS; fibromyalgia syndrome) is a widespreadmusculoskeletal pain and fatigue disorder. Fibromyalgia is characterizedby pain in the muscles, ligaments, and tendons. The condition affectsmore women than men, and occurs in people of all ages. Overall, FMS isestimated to afflict 3-6% of the population. Patients have described thepain associated with fibromylagia as deep muscular aching, throbbing,shooting, and stabbing. The pain sometimes includes an intense burningsensation. The pain and stiffness are often worse in the morning orafter repetitive use of a particular muscle group.

Additionally, varying levels of fatigue ranging from mild toincapacitating are often associated with fibromylagia. Other symptoms offibromylagia include gastrointestinal symptoms. Irritable bowel syndromeand IBS-like symptoms such as constipation, diarrhea, frequent abdominalpain, abdominal gas, and nausea occur in roughly 40 to 70% of FMSpatients. Acid reflux or gastroesophogeal reflux disease (GERD) occursat a similar frequency.

Complex Regional Pain Syndrome (CRPS; also known as chronic regionalpain syndrome) is a chronic pain condition. CRPS was formerly known asreflex sympathetic dystrophy (RSD). CRPS is a chronic, painful, andprogressive neurological condition that affects skin, muscles, joints,and bones. The syndrome usually develops in an injured limb, such as abroken leg or following surgery. However, many cases involve only aminor injury, such as a sprain, and sometimes no precipitating injuriousevent can be identified. CRPS involves continuous, intense pain that isdisproportionate to the severity of the injury. The pain worsens, ratherthan improves, over time.

Although CRPS can affect a variety of regions of the body, it most oftenaffects the arms, legs, hands, or feet. Often the pain begins in oneportion of a limb, but spreads over time to include the entire limb oreven to include a different limb. Typical features include dramaticchanges in the color and temperature of the skin over the affected limbor body part, accompanied by intense burning pain, skin sensitivity,sweating, and swelling.

The compounds disclosed herein can also be used to treat endometriosisand the pain associated therewith.

Neurological or Neurodegenerative Diseases and Disorders

Neurodegenerative diseases and disorders include but are not limited toAlzheimer's disease (AD), Parkinson's disease, Huntington's disease,amyotrophic lateral sclerosis (ALS), and other brain disorders caused bytrauma or other insults including aging.

Mechanisms associated with calcium signaling may be altered in manyneurodegenerative diseases and in disorders resulting from brain injury.For example, fibroblasts or T-lymphocytes from patients with AD haveconsistently displayed an increase in Ca²⁺ release from intracellularstores compared to controls (Ito et al. (1994) Proc. Natl. Acad. Sci.U.S.A. 91:534-538; Gibson et al. (1996) Biochem. Biophys. ACTA1316:71-77; Etchenberrigaray et al. (1998) Neurobiology of Disease,5:37-45). Consistent with these observations, mutations in presenilingenes (PS1 or PS2) associated with familial AD (FAD) have been shown toincrease InsP3-mediated Ca²⁺ release from internal stores (Guo et al.(1996) Neuro Report, 8:379-383; Leissring et al. (1999) J.Neurochemistry, 72:1061-1068; Leissring et al. (1999) J. Biol. Chem. 274(46):32535-32538; Leissring et al. (2000) J. Cell Biol. 149 (4):793-797;Leissring et al. (2000) Proc. Natl. Acad. Sci. U.S.A. 97(15):8590-8593). Furthermore, mutations in PS1 or PS2 associated with anincrease in amyloidogenic amyloid β peptide generation in AD arereported to be associated with a decrease in intracellular calcium level(Yoo et al. (2000) Neuron, 27 (3):561-572).

Experimental traumatic brain injury has been shown to initiate massivedisturbances in Ca²⁺ concentrations in the brain that may contribute tofurther neuronal damage. Intracellular Ca²⁺ may be elevated by manydifferent ion channels. It has been further shown that channel blockersmay be beneficial in the treatment of neurological motor dysfunctionwhen administered in the acute posttraumatic period (Cheney et al.(2000) J. Neurotrauma, 17 (1):83-91).

Seizure

Excitotoxicity of a variety of origins leads to seizures. Commonlyexcess neuronal firing can drive seizure activity. Compounds that reducethe hyperexcitability of relevant neuronal populations have significantpotential in reducing seizure activity.

Proteinuric Kidney Disease

TRPC5 is also expressed in the podocyte of the kidney. It has beenproposed that there is an antagonistic regulation of actin dynamics andcell in the podocytes by TRPC5 and TRPC6 (Tian et al., (2010) ScienceSignaling). Thus, inhibiting TRPC5 may impact the reaction of thepodocyte to injury.

Combination Therapy

The present invention provides a compound of Formula (I) for use invitro and in vivo. The present invention also provides compositions andpharmaceutical compositions comprising a compound of Formula (I) thatinhibits TRPC5 activity. In certain embodiments, the compound of Formula(I) is selective. In other words, in certain embodiments, the compoundof Formula (I) inhibits TRPC5 activity preferentially over the activityof other ion channels. In certain embodiments, the compound of Formula(I) inhibits TRPC5 activity preferentially over TRPV1, TRPV2, TRPV3,TRPV4, TRPC3, TRPC6, TRPC7, TRPA1, and/or TRPM8 activity. For example,in certain embodiments, the compound of Formula (I) inhibits theactivity of TRPC5 and also inhibits the activity of one or more ofTRPC4, TRPV1, TRPV2, TRPV3, TRPV4, TRPC3, TRPC6, TRPC7, TRPA1, andTRPM8.

A compound of Formula (I) can be used alone or in combination with otherpharmaceutically active agents. Examples of such other pharmaceuticallyactive agents include, but are not limited to, anti-depressants,anti-anxiety agents, anti-epileptic agents, anti-inflammatory agents(e.g., NSAIDS, bradykinin receptor antagonists, hormones and autacoidssuch as corticosteroids), or anti-migraine agents. Certain active agentsbelong to more than one category.

In certain embodiments, a compound of Formula (I) is conjointlyadministered with an analgesic. Suitable analgesics include, but are notlimited to, opioids, glucocorticosteroids, non-steroidalanti-inflammatories, naphthylalkanones, oxicams, para-aminophenolderivatives, propionic acids, propionic acid derivatives, salicylates,fenamates, fenamate derivatives, pyrozoles, and pyrozole derivatives.Examples of such analgesic compounds include, but are not limited to,codeine, hydrocodone, hydromorphone, levorpharnol, morphine, oxycodone,oxymorphone, butorphanol, dezocine, nalbuphine, pentazocine, etodolac,indomethacin, sulindac, tolmetin, nabumetone, piroxicam, acetaminophen,fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen, diclofenac,oxaprozin, aspirin, diflunisal, meclofenamic acid, mefanamic acid,prednisolone, and dexamethasone. Preferred analgesics are non-steroidalanti-inflammatories and opioids (preferably morphine).

In some embodiments, a compound of Formula (I) can be administered inconjunction with a therapeutic whose administration causes pain. Forexample, a compound of Formula (I) can be administered in conjunctionwith an anesthetic, to reduce the pain caused by the administration ofthe anaesthetic. A compound of Formula (I) can also be administered inconjunction with a chemotherapeutic agent, to reduce the pain caused byadministration of the chemotherapeutic agent.

In certain embodiments, a compound of Formula (I) is conjointlyadministered with a non-steroidal anti-inflammatory. Suitablenon-steroidal anti-inflammatory compounds include, but are not limitedto, piroxicam, diclofenac, etodolac, indomethacin, ketoralac, oxaprozin,tolmetin, naproxen, flubiprofen, fenoprofen, ketoprofen, ibuprofen,mefenamic acid, sulindac, apazone, phenylbutazone, aspirin, celecoxiband rofecoxib.

Pharmaceutical Compositions

Suitable preparations for administering the compounds of the presentinvention will be apparent to those with ordinary skill in the art andinclude for example tablets, pills, capsules, suppositories, lozenges,troches, solutions, syrups, elixirs, sachets, injectables, inhalatives,powders, etc. The content of the pharmaceutically active compound(s)should be in the range from 0.1 to 95 wt.-%, preferably 5.0 to 90 wt.-%of the composition as a whole.

Suitable tablets may be obtained, for example, by mixing one or morecompounds of the present invention with known excipients, for exampleinert diluents, carriers, disintegrants, adjuvants, surfactants, bindersand/or lubricants. The tablets may also consist of several layers.

Dosages

The dose range of the compounds of the invention applicable per day isusually from 1 to 1000 mg, preferably from 5 to 800 mg, more preferablyfrom 25 to 500 mg. Each dosage unit may conveniently contain from 1 to1000 mg, preferably 25 to 500 mg.

The actual pharmaceutically effective amount or therapeutic dosage willof course depend on factors known by those skilled in the art such asage and weight of the patient, route of administration and severity ofdisease. In any case the combination will be administered at dosages andin a manner which allows a pharmaceutically effective amount to bedelivered based upon patient's unique condition.

Disease and Injury Models

A compound of Formula (I) which antagonizes TRPC5 function may be usefulin the prophylaxis and treatment of any of the foregoing injuries,diseases, disorders, or conditions. In addition to in vitro assays ofthe activity of the compound of Formula (I), its efficacy can be readilytested in one or more animal models. By way of example, numerous wellknown animal models exist. One or more suitable animal models (e.g.,suitable in light of the particular indication) can be selected.

Fear-related behaviors can be measured as described, e.g., in Riccio etal. Pain behaviors can be studied using various agents or procedures tosimulate pain resulting from injuries, diseases, or other conditions.Blackburn-Munro (2004) Trends in Pharmacological Sciences 25:

299-305. Behavioral characteristics of challenged animals can then beobserved. Compounds or procedures that may reduce pain in the animalscan be readily tested by observing behavioral characteristics ofchallenged animals in the presence versus the absence of the testcompound(s) or procedure.

Exemplary behavioral tests used to study chronic pain include tests ofspontaneous pain, allodynia, and hyperalgesia. Id. To assess spontaneouspain, posture, gait, nocifensive signs (e.g., paw licking, excessivegrooming, excessive exploratory behavior, guarding of the injured bodypart, and self-mutilation) can be observed. To measure evoked pain,behavioral responses can be examined following exposure to heat (e.g.,thermal injury model).

Exemplary animal models of pain include, but are not limited to, theChung model, the carageenan induced hyperalgesia model, the Freund'scomplete adjuvant induced hyperalgesia model, the thermal injury model,the formalin model and the Bennett Model. The Chung model of neuropathicpain (without inflammation) involves ligating one or more spinal nerves.Chung et al. (2004) Methods Mol Med 99: 35-45; Kim and Chung (1992) Pain50: 355-363. Ligation of the spinal nerves results in a variety ofbehavioral changes in the animals including heat hyperalgesia, coldallodynia, and ongoing pain. Compounds that antagonize TRPC5 can beadministered to ligated animals to assess whether they diminish theseligation-induced behavioral changes in comparison to that observed inthe absence of compound.

Useful anxiety and depression models include the maternal separationmodel, the elevated plus-maze model, the forced swim test, the tailsuspension test, the light/dark preference model, the light-enhancedstartle model, and the ultrasonic vocalization model.

Useful seizure models include but are not limited to maximal electricshock (MES), acoustic startle in susceptible animals (eg DBA mice), andchemical induced seizure (with proconvulsant compounds such aspilocarpine, pentalene tetrazole, kainic acid, N-methyl-D-asparticacid).

Useful models of kidney function include the LPS-induced proteinuria(waiting for a reference for others).

EXAMPLES Example 1 High Throughput Screening Assay

The assay depended on detection of the rise in intracellular Ca2+concentration ([Ca2+]i) following channel activation in cells induciblyexpressing the TRPC5 channel. Ca2+ rise was quantified with the use offluorescent Ca2+ indicators that were loaded into cells and thereafterindicated the [Ca2+]i Ca2+ influx followed activation of the TRPC5channel. Compounds inhibiting the [Ca2+]i rise were considered hits forfurther investigation.

The commercially available HEK293/TREx line (Invitrogen) was stablytransfected with a TRPC5 construct and screened by conventional calciumimaging to find clones with TRPC5 expression following stimulation with1 μg/ml tetracycline. These cells were maintained in the growth mediumrecommended by the manufacturer supplemented with 100 μg/ml hygromycinto promote retention of the TRPC5 construct. After growing to nearconfluency, cells were plated at a density of ˜35,000 cells/well in 384well CellBind plates (Corning) in the presence of 1 μg/ml tetracycline,and allowed to grow for 20-30 hrs. A nearly confluent monolayerresulted. Cells were then loaded with Ca2+ dye: Fura-2/AM or Fluo4/AMwas added to the wells to a final concentration of 4 μM or 0.5 μM,respectively, and incubated for 80 min or 60 min, respectively, at roomtemperature. Supernatant was then removed from the cells by invertingplates with a sharp flick, and 25 μl Hank's Balanced Salt Solution(HBSS; 0.185 g/l D-glucose, 0.9767 g/l MgS04 (anhydrous), 0.4 g/l KCl,0.06 g/l KH2PO4 (anhydrous), 0.35 g/l NaHCO3, 8.0 g/l NaCl, and 0.04788g/l Na2HPO4 (anhydrous); pH 7.4) was then added to each well. Following˜0.5 hour for recovery from loading, cells were assayed using theHamamatsu FDSS 6000 system, which permitted illumination alternately at340 nm and 380 nm for Fura-2 experiments, or at 485 nm for Fluo4experiments. Frames were acquired at a rate of 0.2 Hz. During the assay,the plates were continuously vortexed, with pipette mixing of wellsfollowing addition of each reagent. For the screening assay, 26 μl of adiluted compound stock (at 50 μM) was added to each well for 2 minutesfollowing the collection of a short (4 frame) baseline. 13 μl 62 mMhigh-Ca2+ Ringer solution (4.17 ml of normal ringer (with 2 mM Ca2+)plus 5.83 ml of isotonic calcium ringer (105 mM Ca2+; in this ringer allsodium has been replaced with calcium)) was then added to each well,achieving a final concentration of 14 mM Ca2+ and 10 μM test compound.Data was collected for ˜3 minutes following addition of high Ca2+Ringer,where the fluorescent intensity (for Fluo4) and the F340/F380 ratio (forFura-2) were proportional to the [Ca2+]i Negative controls consisted ofHEK293/TREx TRPC5 cells exposed to high Ca2+ solution, but no compound.Positive control conditions consisted of addition of 2-APB, apromiscuous blocker of TRPC5 and other channels, to columns 23 and 24 ofthe plates, to a final concentration of 200 μM. These controls defined ascreening window, and “hits” were defined as those compounds inhibitingthe fluorescence response by at least 40%. IC50 values were determinedfor compounds defined as “hits.” The Fluo4 cell-based fluorescence assaywas used to determine the intracellular Ca2+ concentration in thepresence of varying drug concentration. Final concentrations ofcompounds tested were 20 μM, 6.667 μM, 2.222 μM, 0.741 μM, 0.247 μM,0.082 μM, and 0.027 μM. Compounds were tested in triplicate at allconcentrations. Standard software was used to fit IC50 curves.

Additionally or alternatively, efficacy can be represented as %inhibition in the presence (of a given concentration of compound) versusthe absence of compound or in comparison to a control compound. Forexample, efficacy can be represented as % inhibition of ion flux in thepresence versus the absence of compound. Exemplary compounds are shownin Table 2 below.

TABLE 2 Compound IC₅₀ Number (nM) 29 421 30 503 32 2940 33 832 34 308035 780 36 7540 37 408

Example 2 Patch Clamp Experiments

Patch clamp experiments permit the detection of currents through theTRPC5 channel in the cell line described above. In normal whole-cellpatch clamp recordings, a glass electrode is brought into contact with asingle cell and a high-resistance (gigaohm) seal is established with thecell membrane. The membrane is then ruptured to achieve the whole-cellconfiguration, permitting control of the voltage of the cell membraneand measurement of currents flowing across the membrane using theamplifier attached to the electrode and resulting in the replacement ofcytoplasm with the pipette solution. A perfusion system permits controlof the extracellular solution, including the addition of blockers andactivators of the current. The current can be activated by including 1.4μM free Ca²⁺ in the pipette (intracellular) solution, and 80 μM LaCl₃ inthe extracellular solution.

TRPC5 cells were induced 20-48 hours, removed from growth plates, andreplated at low density (to attain good single-cell physical separation)on glass coverslips for measurement. In some cases, cells were grown inlow density overnight on glass coverslips. Patch clamp recordings weremade in the whole-cell mode with a holding potential of −40 mV. Every 5seconds, a voltage ramp was applied from −120 to +100 mV, 400 ms induration. Currents elicited were quantified at −80 mV and +80 mV. Theinternal solution consisted of 140 mM cesium aspartate, 10 mM HEDTA, 2mM CaCl₂, 2.27 mM MgCl₂ and 10 mM HEPES, pH 7.2, with 1,400 nMcalculated free Ca²⁺. The external solution consisted of 150 mM NaCl,4.5 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 10 mM HEPES, 10 mM glucose, 1 mMEGTA, pH 7.4. Upon addition of LaCl₃, TRPC5 current was induced only inTRPC5-expressing cells and not in parental HEK293 TREx cells. Removal ofthe LaCl₃ stimulus causes most of the current to go away. Potentialblockers were tested for ability to block both inward and outwardcurrents in the continued presence of LaCl₃.

IC₅₀ of a compound of Formula (I) was estimated by testing the compoundat 5 μM and 500 nM. When 5 μM of a compound showed no block, IC₅₀ wasestimated as >10 μM. When 5 μM of a compound showed 50% or less block, arough estimate of IC₅₀ in the range of 5-10 μM could be made. IC₅₀ for acompound of Formula (I) between 500 nM and 5 μM was similarly estimated.Exemplary compounds are shown in Table 3 below

TABLE 3 Compound IC₅₀ Number (nM) 30 1.14 37 <1

Example 3 General Experimental Procedures

General Procedures

All reagents were purchased from commercial suppliers and used withoutfurther purification unless otherwise stated. Reactions were monitoredvia thin layer chromatography (TLC) on silica gel plates and visualizedusing UV light (254 nm or 365 nm) and/or staining with a solution of DNP(12 g of 2,4-dinitrophenylhydrazine dissolved in H₂SO₄ (60 mL), water(80 mL) and ETOH (200 mL) and subsequent heating or monitored by LCMS.Preparative TLC plates used were Analtech Uniplate Silica Gel GF platesor Shanghia SANPONT PLC plate SGF254 20×20 cm size and 2000 umthickness.

All reactions were run under an inert atmosphere using either argon ornitrogen. All non-aqueous reactions were run using anhydrous solvents.All reactions were stirred either with a magnetic stir bar or withoverhead mechanical stirring. All saturated extraction solutions areassumed to be aqueous (NH₄Cl for example). All drying agents areanhydrous. Drying organic solutions with a drying agent implies that thedrying agent was removed from the organic solution by filtration.Chromatography refers to column chromatography on silica gel.Concentration of reaction mixtures implies concentration under reducedpressure using of a Rotary Evaporation instrument. Drying of finalproducts implies drying under high vacuum conditions. (MW) means using amicrowave instrument with reaction carried out in a sealed microwavevial. Microwave reactions were carried out using a Biotage SmithSynthesizer.

LCMS were performed on a SHIMADZU LCMS-2010EV instrument using one oftwo sets of conditions. LCMS conditions one: (Chromolith SdeedROP,RP-18e column. 50×4.6 mm. mobile phase: Solvent A:CH₃CN/H₂O/HCOOH=10/90/0.05. Solvent B: CH₃CN/H₂O/HCOOH=90/10/0.05, 0.8min @ 10% B. 2.7 min gradient (10-95% B), then 0.8 min @95% B. Flowrate: 3 mL/min. temperature: 40° C.). LCMS conditions two: (Zorbax. 3.5micron. 2.1×50 mm C18 column. Mobile phase: Solvent A: 0.1% HCOOH/CH₃CN.Solvent B: 0.1% HCOOH/H₂O. Gradient 5% to 95% B using a 5 min or 8 minruntime.

Preparative HPLC was performed either on a SHIMADZU LC-8A instrument.(Column: YMC Pack ODS-A (150*30 mm 10 um)) or LC-6AD (column: Shim=PackPREP-ODS-H (250*20 mm, 10 um)) with UV detection which was controlled byLC solution Chemstation software. H₂O (0.1% HCOOH) and methanol (CH₃OH)as mobile phase at the indicated flow rate.

Analytical HPLC was performed on a SHIMADZU LCMS-2010EV (ChromolithSpeedROD, RP-18e, 50×4.6 mm, mobile phase: Solvent A:CH₃CN/H₂O/HCOOH=10/90/0.05, Solvent B: CH₃CN/H₂O/HCOOH=90/10/0.05, 0.8min@ 10% B, 2.7 min gradient (10-95% B), then 0.8 min@95% B, Flow rate:3 mL/min, temperature: 40° C.

¹H NMR spectra were recorded on either a Bruker Avance II 400 MHz or aVarian Unity Inova 400 MHz instrument. Chemical shifts (δ) are reportedin ppm relative to tetramethylsilane (δ=o.oo ppm) and the spectra werecalibrated to the residual solvent signal of Chloroform (δ=7.26).Dimethyl sulfoxide (δ=2.52), methanol (δ=3.34). Data for ¹H NMR spectraare reported as follows: chemical shift (multiplicity, J value, numberof hydrogens). Abbreviations are as follows: s (singlet), d (doublet), t(triplet), td (doublet of triplets) q (quartet), quint (quintet), m(multiplet), brd (broad).

LIST OF ABBREVIATIONS AND TERMS

AcONa sodium acetate

Ac₂O acetic anhydride

aq. aqueous

Bn benzyl

Celite diatomaceous earth

CDCl₃ deuterated chloroform

CDI 1,1′-carbonyldiimidazole

CD₃OD deuterated methanol

d deuterated

DCM dichloromethane

DHP dihydropyran

DIPEA diisopropylethylamine

DMA dimethylacetamide

DMAP 4-dimethylaminopyridine

DMF N,N-dimethylformamide

DMSO dimethyl sulfoxide

DMSO-d₆ deuterated DMSO

EA ethyl acetate

ETOH ethanol 200 proof

h hours

Hex hexanes

Hep heptanes

HPLC high pressure liquid chromatography

HOAc acetic acid

IBX 2-iodobenzoic acid

LAH lithium aluminum hydride

LCMS liquid chromatography-mass spectrometry

LDA lithium diisopropylamine

MeOH methanol

M molarity

mmol millimolar

mg milligrams

mL milliliters

min minutes

MW microwave reactor

MTBE methyl tert-butyl ether

Na sodium

n-BuLi n-butyllithium

N normality

NCS n-chlorosuccinimide

NBS n-bromosuccinimide

NMR nuclear magnetic resonance

Pd/C palladium on activated carbon

Pd(dppf)Cl₂ [1,1′Bis(diphenylphosphino)ferrocene]dichloropalladium(II)

Pd(PPh₃)₄ Bis(triphenylphosphine)palladium(II) dichloride

PE petroleum ether

PPTS pyridinium p-toluenesulfonate

Prep TLC preparative thin layer chromatography

Prep HPLC preparative high pressure liquid chromatography

psi pounds per square inch

RT room temperature

SEM 2-(trimethylsilyl)ethoxymethyl

TBAI tetrabutylammonium iodide

TBAF tetrabutylammonium fluoride

TBS t-butyldimethyl silyl

TEA triethylamine

TFA trifluoroacetic acid

THP tetrahydropyranyl

TLC thin layer chromatography

THF tetrahydrofuran

T_(r) LCMS retention time

Preparation of Compounds Intermediate 13-(3-hydroxypropyl)-1-methyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 1: 1,6-dimethylpyrimidine-2,4(1H,3H)-dione

A solution of 1-methylurea (30 g, 0.356 mol) in 4-methyleneoxetan-2-one(26.4 g, 0.356 mol) was heated at 100° C. for 18 h, cooled to RT thendiluted with MeOH (50 mL). The reaction was filtered and the filteredsolid was washed with MeOH (20 mL) and dried to give1,6-dimethylpyrimidine-2,4(1H,3H)-dione (9 g, 18% yield) as a whitesolid. ¹H NMR (CDCl₃) δ: 8.33 (s, 1H), 5.58 (s, 1H), 3.38 (s, 3H), 2.26(s, 3H). LCMS: MH⁺ 141 and T_(R)=0.368 min. Used without furtherpurification.

Step 2: 1,6-dimethyl-5-nitropyrimidine-2,4(1H,3H)-dione

To a solution of 1,6-dimethylpyrimidine-2,4(1H,3H)-dione (5 g, 0.035mol) in H₂SO₄ (20 mL) at 0° C. was added dropwise a solution of KNO₃(4.69 g, 0.046 mol) in H₂SO₄ (10 mL). The reaction was stirred 0° C. for2 h, warmed to RT, stirred for 18 h, poured into ice then extracted withEA (5×50 mL). The combined organic layers were dried over Na₂SO₄, andconcentrated to give 1,6-dimethyl-5-nitropyrimidine-2,4(1H,3H)-dione(4.3 g, 68.1% yield) as a yellow solid. ¹H NMR (DMSO-d₆) δ: 12.09 (s,1H), 3.32 (s, 3H), 2.36 (s, 3H) LCMS: MH⁺ 186 and T_(R)=0.610 min. Usedwithout further purification.

Step 3:1,6-dimethyl-5-nitro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyrimidine-2,4(1H,3H)-dione

To a solution of 1,6-dimethyl-5-nitropyrimidine-2,4(1H,3H)-dione (6 g,0.032 mol) in DMF (20 mL) was added2-(3-bromopropoxy)tetrahydro-2H-pyran (10.85 g, 0.049 mol) and K₂CO₃(13.44 g, 0.097 mol). The reaction was heated at 65° C. for 2 h, cooledto RT then diluted with EA (20 mL) and water (20 mL). The organic layerwas washed with aq. 1N LiCl (3×30 mL), dried over Na₂SO₄ andconcentrated to a residue which was purified by chromatography elutedwith PE/EA (5:1 to 1:1) to give1,6-dimethyl-5-nitro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyrimidine-2,4(1H,3H)-dione (5 g, 47.1% yield) as a yellow oil. LCMS:[MH⁺-THP] 244 and T_(R)=1.180 min. Used without further purification.

Step 4:(E)-3-(3-methyl-5-nitro-2,6-dioxo-4-(3-(trifluoromethoxy)styryl)-2,3-dihydropyrimidin-1(6H)-yl)propylacetate

To a solution of1,6-dimethyl-5-nitro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyrimidine-2,4(1H,3H)-dione(1 g, 3.05 mmol) in HOAc (4 mL) was added3-(trifluoromethoxy)benzaldehyde (0.755 g, 3.97 mmol) and sodium acetate(0.752 g, 9.16 mmol). The reaction was heated at 140° C. for 6 h, cooledto RT then diluted with EA (20 mL) and water (20 mL). The organic layerwas dried over Na₂SO₄ and concentrated to a residue which was purifiedby chromatography PE/EA (5:1 to 2:1) to give(E)-3-(3-methyl-5-nitro-2,6-dioxo-4-(3-(trifluoromethoxy)styryl)-2,3-dihydropyrimidin-1(6H)-yl)propylacetate (200 mg, 14.3% yield) as a brown oil. LCMS: MH⁺ 458 andT_(R)=1.689 min.

Step 5:3-(1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of(E)-3-(3-methyl-5-nitro-2,6-dioxo-4-(3-(trifluoromethoxy)styryl)-2,3-dihydropyrimidin-1(6H)-yl)propyl acetate (50 mg, 0.109 mmol) in HCOOH (3 mL)was added Na₂S₂O₄ (114.0 mg, 0.655 mmol). The reaction was heated at140° C. for 5 h, cooled to RT then diluted with EA (20 mL) and water (20mL). The organic layer was dried over Na₂SO₄ and concentrated to give3-(1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (20 mg, 43.1% yield) as an oil. LCMS: MH⁺ 426 and T_(R)=1.597min. Used without further purification.

Compound 295-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1,7-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 13-(5-(4-chlorobenzyl)-1,7-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(1,7-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (See Compound 36, Step 2, 140 mg, 0.319 mmol) in DMF (2 mL) wasadded 1-chloro-4-(chloromethyl)benzene (102.6 mg, 0.637 mmol) followedby K₂CO₃ (132.1 mg, 0.956 mmol). The reaction was heated at 85° C. for 2h, cooled to RT then diluted with EA (10 mL) and brine (5 mL). Theorganic layer was washed with aqueous 1N LiCl (3×20 mL), dried overNa₂SO₄ and concentrated to give3-(5-(4-chlorobenzyl)-1,7-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (120 mg, 66.7% yield) LCMS: MH⁺ 564 and T_(R)=2.151 min. Usedwithout further purification.

Step 25-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1,7-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

To a solution of3-(5-(4-chlorobenzyl)-1,7-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (120 mg, 0.212 mmol) in THF (5 mL) and water (5 mL) was addedLiOH.H₂O (17.9 mg, 0.425 mmol). The reaction was stirred at RT for 30min then diluted with DCM (5 mL) and water (5 mL). The organic layer wasdried over Na₂SO₄ and concentrated to a residue which was purified byPrep HPLC to give5-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1,7-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione (15 mg, 27% yield) as a white solid. ¹H NMR (CDCl₃) δ:7.49 (t, J=8.0 Hz, 1H), 7.32 (d, J=8.3 Hz, 1H), 7.13 (dd, J=16.3, 8.0Hz, 3H), 7.04 (s, 1H), 6.71 (d, J=8.4 Hz, 2H), 5.46 (s, 2H), 4.31-4.15(m, 2H), 3.74 (s, 3H), 3.65 (s, 1H), 3.50 (s, 2H), 2.20 (s, 3H),1.98-1.81 (m, 2H). LCMS: MH⁺ 522 and T_(R)=3.111 min.

Compound 305-(4-chlorobenzyl)-6-(3-chlorophenyl)-3-(3-hydroxypropyl)-1-methyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 1(E)-3-(4-(3-chlorostyryl)-3-methyl-5-nitro-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)propylacetate

To a solution of3-(3,4-dimethyl-5-nitro-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)propylacetate (300 mg, 1.05 mmol) in HOAc (0.7 mL) was added3-chlorobenzaldehyde (221 mg, 1.58 mmol) and sodium acetate (431 mg,5.26 mmol). The reaction was heated at 150° C. for 7 h, cooled to RTthen diluted with EA (20 mL) and water (20 mL). The organic layer wasdried over Na₂SO₄ and concentrated to a residue which was purified bychromatography PE/EA (5:1 to 2:1) to give(E)-3-(4-(3-chlorostyryl)-3-methyl-5-nitro-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)propyl acetate (70 mg, 16.4% yield) as a brown oil. LCMS: MH⁺408 and T_(R)=1.560 min.

Step 23-(6-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of(E)-3-(4-(3-chlorostyryl)-3-methyl-5-nitro-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)propylacetate (70 mg, 0.172 mmol) in HCOOH (3 mL) was added Na₂S₂O₄ (180.0 mg,1.032 mmol). The reaction was heated at 110° C. for 5 h, cooled to RTthen diluted with EA (20 mL) and water (20 mL). The organic layer wasdried over Na₂SO₄ and concentrated to give3-(6-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate(60 mg, 93.0% yield) as an oil. LCMS: MH⁺ 375 and T_(R)=1.467 min. Usedwithout further purification.

Step 33-(5-(4-chlorobenzyl)-6-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a mixture of3-(6-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (60 mg, 0.16 mmol), K₂CO₃ (110 mg, 0.80 mmol) in DMF (2 ml) wasadded 1-chloro-4-(chloromethyl)benzene (51 mg, 0.32 mmol). The reactionwas heated at 85° C. for 2 h, cooled to RT then diluted with EA (20 mL)and water (20 mL). The organic layer was dried over Na₂SO₄ andconcentrated to give3-(5-(4-chlorobenzyl)-6-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (40 mg, 50% yield) as an oil. LCMS: MH⁺ 500 and T_(R)=1.847 min.Used without further purification.

Step 45-(4-chlorobenzyl)-6-(3-chlorophenyl)-3-(3-hydroxypropyl)-1-methyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

To a solution of3-(5-(4-chlorobenzyl)-6-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (40 mg, 0.08 mmol) in THF (1.5 mL) and water (1.5 mL) was addedLiOH.H₂O (30.0 mg, 0.6 mmol). The reaction was stirred at RT for 30 mindiluted with EA (10 mL) and water (10 mL). The organic layer was driedover Na₂SO₄ and concentrated to a residue which was purified by PrepHPLC to give5-(4-chlorobenzyl)-6-(3-chlorophenyl)-3-(3-hydroxypropyl)-1-methyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione(3 mg, 3.3% yield) as a white solid. ¹H NMR (CDCl₃) δ: 7.47-7.31 (m,3H), 7.24-7.15 (m, 3H), 6.84 (d, J=8.4 Hz, 2H), 6.08 (s, 1H), 5.58 (s,2H), 4.26-4.14 (m, 2H), 3.60 (s, 1H), 3.51 (s, 5H), 1.93-1.82 (m, 2H).LCMS: MH⁺ 458 and T_(R)=2.885 min.

Compound 323-(3-hydroxypropyl)-1,5-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 13-(1,5-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (See Intermediate 1, 50 mg, 0.118 mmol) in DMF (2 mL) was addedCH₃I (50 mg, 0.353 mmol) followed by K₂CO₃ (48.7 mg, 0.353 mmol). Thereaction was heated at 85° C. for 2 h then diluted with EA (10 mL) andbrine (5 mL). The organic layer was washed with aq. 1N LiCl (3×30 mL),dried over Na₂SO₄ and concentrated to give3-(1,5-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propyl acetate (30 mg, 58.1% yield) as an oil. LCMS: MH⁺ 440 andT_(R)=1.711 min. Used without further purification.

Step 23-(3-hydroxypropyl)-1,5-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

To a solution of3-(1,5-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (30 mg, 0.068 mmol) in THF (5 mL) and water (5 mL) was addedLiOH.H₂O (5.73 mg, 0.136 mmol). The reaction was stirred at RT for 30min then diluted with DCM (5 mL) and water (5 mL). The organic layer wasdried over Na₂SO₄ and concentrated to a residue which was purified byPrep HPLC to give3-(3-hydroxypropyl)-1,5-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione(10 mg, 36.9% yield) as a white solid. ¹H NMR (CDCl₃) δ: 7.54 (t, J=7.9Hz, 1H), 7.38 (d, J=7.8 Hz, 1H), 7.32 (d, J=11.0 Hz, 2H), 6.03 (s, 1H),4.29-4.17 (m, 2H), 3.98 (s, 3H), 3.72 (s, 1H), 3.54 (t, J=5.1 Hz, 2H),3.50 (s, 3H), 1.99-1.84 (m, 2H). LCMS: MH⁺ 398 and T_(R)=2.507 min.

Compound 333-(3-hydroxypropyl)-1,5,7-trimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 13-(7-bromo-1,5-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(7-bromo-1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (See Compound 36, Step 1, 25 mg, 0.050 mmol) in DMF (1 mL) wasadded CH₃I (14.1 mg, 0.10 mmol) followed by K₂CO₃ (20.6 mg, 0.15 mmol).The reaction was heated at 85° C. for 1.5 h, cooled to RT then dilutedwith EA (10 mL) and brine (5 mL). The organic layer was washed with aq.1N LiCl (3×20 mL), dried over Na₂SO₄ and concentrated to give3-(7-bromo-1,5-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (25 mg, 97.3% yield) as an oil. LCMS: MH⁺ 518 and T_(R)=1.877min. Used without further purification.

Step 23-(1,5,7-trimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(7-bromo-1,5-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (25 mg, 0.05 mmol) in DMF (1 mL) was added tetramethylstannane(26.7 mg, 0.15 mmol) and Pd(PPh₃)₂Cl₂ (5 mg). The reaction was heated at120° C. (MW) for 45 min, cooled to RT then diluted with EA (5 mL) andwater (5 mL). The organic layer was dried over Na₂SO₄ and concentratedto a residue was purified by chromatography eluted with PE/EA (5:1 to1:1) to give3-(1,5,7-trimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (20 mg, 91.8% yield) as an oil. LCMS: MH⁺ 454 and T_(R)=1.625min. Used without further purification.

Step 33-(3-hydroxypropyl)-1,5,7-trimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

To a solution of3-(1,5,7-trimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (20 mg, 0.044 mmol) in THF (5 mL) and water (5 mL) was addedLiOH.H₂O (3.70 mg, 0.088 mmol). The reaction was stirred at RT for 30min then diluted with DCM (5 mL) and water (5 mL). The organic layer wasdried over Na₂SO₄ and concentrated to give a residue which was purifiedby Prep HPLC to give3-(3-hydroxypropyl)-1,5,7-trimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione(5 mg, 27.6% yield) as a white solid. ¹H NMR (CDCl₃) δ: 7.56 (t, J=8.0Hz, 1H), 7.35 (d, J=8.3 Hz, 1H), 7.24 (d, J=7.7 Hz, 1H), 7.16 (s, 1H),4.33-4.14 (m, 2H), 3.80 (s, 3H), 3.73 (s, 3H), 3.52 (dd, J=12.8, 7.5 Hz,2H), 2.21 (s, 3H), 2.03-1.83 (m, 2H). LCMS: MH⁺ 412 and T_(R)=2.613 min.

Compound 345-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1,7-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 16-(2-(dimethylamino)vinyl)-1-methyl-5-nitro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyrimidine-2,4(1H,3H)-dione

To a solution of1,6-dimethyl-5-nitro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyrimidine-2,4(1H,3H)-dione(980 mg, 3 mmol) in DMF (2 mL) was added DMF-DMA (5 mL). The reactionwas heated at 95° C. for 15 h, cooled to RT and concentrated to aresidue which was dissolved in EA (20 mL). The mixture was washed withaq. 1N LiCl (3×10 mL). The organic layer was dried over Na₂SO₄ andconcentrated to a residue which was purified by chromatography elutedwith PE/EA (2:1) to give6-(2-(dimethylamino)vinyl)-1-methyl-5-nitro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyrimidine-2,4(1H,3H)-dione (840 mg, 73% yield) as a yellow oil. LCMS:MH⁺ 383 and T_(R)=1.308 min.

Step 23-(1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of6-(2-(dimethylamino)vinyl)-1-methyl-5-nitro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)pyrimidine-2,4(1H,3H)-dione(530 mg, 1.4 mmol) in HOAc (5 mL) was added Zn dust (910 mg, 14 mmol).The reaction was heated at 100° C. for 2 h, cooled to RT, diluted withwater (10 mL) and extracted with EA (3×20 mL). The combined organiclayers were dried over Na₂SO₄ and concentrated to a residue which waspurified by chromatography eluted with PE/EA (1:1) to give3-(1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (210 mg, 56% yield) as a white solid. LCMS: MH⁺ 266 andT_(R)=0.646 min.

Step 33-(5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (52 mg, 0.2 mmol) in DMF (3 mL) was added1-chloro-4-(chloromethyl)benzene (64 mg, 0.4 mmol) and K₂CO₃ (82 mg, 0.6mmol). The reaction was heated at 85° C. for 2 h, cooled to RT thendiluted with EA (30 mL) and water (20 mL). The organic layer was washedwith aq. 1N LiCl solution (3×10 mL), dried over Na₂SO₄ and concentratedto give3-(5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (47 mg, 59% yield) as a solid. LCMS: MH⁺ 390 and T_(R)=1.399min. Used without further purification.

Step 43-(7-bromo-5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propyl acetate (1.50 g, 3.85 mmol) in DCM (1 mL) was added NBS(0.68 g, 3.85 mmol). The reaction was stirred at RT for 1 h then dilutedwith DCM (10 mL) and water (5 mL). The organic layer was dried overNa₂SO₄ and concentrated to a residue which was purified bychromatography eluted with PE/EA (5:1 to 1:1) to give3-(7-bromo-5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (1.2 g, 66.5% yield) as a solid. LCMS: MH⁺ 468 and T_(R)=1.777min. Used without further purification.

Step 53-(5-(4-chlorobenzyl)-1,7-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(7-bromo-5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (50 mg, 0.107 mmol) in DMF (2 mL) was added tetramethylstannane(38.2 mg, 0.214 mmol) and Pd(PPh₃)₂Cl₂ (10 mg). The reaction was heatedat 120° C. (MW) for 45 min, cooled to RT then diluted with EA (5 mL) andwater (5 mL). The organic layer was dried over Na₂SO₄ and concentratedto a residue which was purified by chromatography eluted with PE/EA (5:1to 1:1) to give3-(5-(4-chlorobenzyl)-1,7-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (40 mg, 92.8% yield) as an oil. LCMS: MH⁺ 404 and T_(R)=1.630min. Used without further purification.

Step 65-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1,7-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

To a solution of3-(5-(4-chlorobenzyl)-1,7-dimethyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propyl acetate (40 mg, 0.099 mmol) in THF (5 mL) and water(5 mL) was added LiOH.H₂O (4.74 mg, 0.198 mmol). The reaction wasstirred at RT for 30 min then diluted with DCM (5 mL) and water (5 mL).The organic layer was dried over Na₂SO₄ and concentrated to a residuewhich was purified by Prep HPLC to give5-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1,7-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione(15 mg, 41.9% yield) as a white solid. ¹H NMR (DMSO-d₆) δ: 7.38 (d,J=8.4 Hz, 2H), 7.26 (s, 1H), 7.22 (d, J=8.4 Hz, 2H), 5.45 (s, 2H), 4.44(t, J=5.3 Hz, 1H), 3.95-3.82 (m, 2H), 3.56 (s, 3H), 3.45-3.39 (m, 2H),2.26 (s, 3H), 1.73-1.58 (m, 2H). LCMS: MH⁺ 362 and T_(R)=2.343 min.

Compound 355-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1-methyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 13-(5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of tert-butyl3-(1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (See Intermediate 1, 60 mg, 0.141 mmol) in DMF (2 mL) was added1-chloro-4-(chloromethyl)benzene (45.4 mg, 0.282 mmol), followed byK₂CO₃ (58.5 mg, 0.423 mmol). The reaction was heated at 85° C. for 18 h,cooled to RT then diluted with EA (10 mL) and brine (5 mL). The organiclayer was washed with aq. 1N LiCl (3×20 mL), dried over Na₂SO₄ andconcentrated to a residue which was purified by chromatography PE/EA(5:1 to 2:1) to give3-(5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (30 mg, 38.7% yield) as a solid. LCMS: MH⁺ 550 and T_(R)=2.078min.

Step 25-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1-methyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

To a solution of3-(5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (30 mg, 0.054 mmol) in THF (5 mL) and water (5 mL) was addedLiOH.H₂O (4.58 mg, 0.109 mmol). The reaction was stirred at RT for 30min then diluted with DCM (5 mL) and water (5 mL). The organic layer wasdried over Na₂SO₄ and concentrated to a residue which was purified byPrep HPLC to give5-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1-methyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione (4 mg, 14.4% yield) as a white solid. ¹H NMR (CDCl₃) δ:7.47 (t, J=8.0 Hz, 1H), 7.31 (d, J=8.6 Hz, 1H), 7.26-7.24 (m, 1H), 7.20(d, J=8.3 Hz, 3H), 6.81 (d, J=8.4 Hz, 2H), 6.10 (s, 1H), 5.59 (s, 2H),4.26-4.13 (m, 2H), 3.56 (d, J=6.7 Hz, 1H), 3.50 (d, J=9.8 Hz, 5H), 1.90(d, J=5.4 Hz, 2H). LCMS: MH⁺ 508 and T_(R)=3.007 min.

Compound 363-(3-hydroxypropyl)-1,7-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 13-(7-bromo-1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (See Intermediate 1, 170 mg, 0.40 mmol) in HOAc (3 mL) was addedBr₂ (76.6 mg, 0.48 mmol). The reaction was stirred at RT for 2 h thendiluted with EA (10 mL) and water (5 mL). The organic layer was washedwith water (3×20 mL), dried over Na₂SO₄ and concentrated to a residuewhich was purified by chromatography eluted with PE/EA (5:1) to give3-(7-bromo-1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (150 mg, 74.4% yield) as a yellow oil. LCMS: MH⁺ 504 andT_(R)=1.739 min.

Step 23-(1,7-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(7-bromo-1-methyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (150 mg, 0.297 mmol) in dioxane (2 mL) was added2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (112.0 mg, 0.892 mmol),Cs₂CO₃ (290.8 mg, 0.892 mmol) and Pd(dppf)Cl₂ (20 mg, 0.0274 mmol). Thereaction was heated at 150° C. (MW) for 30 min, cooled to RT thendiluted with EA (5 mL) and water (5 mL). The organic layer was driedover Na₂SO₄ and concentrated to give3-(1,7-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propyl acetate (120mg, 91.8% yield) as a solid. LCMS: MH⁺ 440 and T_(R)=1.571 min.

Step 33-(3-hydroxypropyl)-1,7-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

To a solution of3-(1,7-dimethyl-2,4-dioxo-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (40 mg, 0.091 mmol) in THF (5 mL) and water (5 mL) was addedLiOH.H₂O (7.64 mg, 0.182 mmol). The reaction was stirred at RT for 30min then diluted with DCM (5 mL) and water (5 mL). The organic layer wasdried over Na₂SO₄ and concentrated to a residue which was purified byPrep HPLC to give3-(3-hydroxypropyl)-1,7-dimethyl-6-(3-(trifluoromethoxy)phenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione(10 mg, 27.6% yield) as a white solid. ¹H NMR (CDCl₃) δ: 9.58 (s, 1H),7.54 (t, J=7.9 Hz, 1H), 7.42 (d, J=7.8 Hz, 1H), 7.31 (d, J=9.9 Hz, 2H),4.30-4.09 (m, 2H), 3.76 (s, 3H), 3.64 (t, J=7.1 Hz, 1H), 3.56-3.41 (m,2H), 2.42 (s, 3H), 1.92-1.74 (m, 2H). LCMS: MH⁺ 398 and T_(R)=2.418 min.

Compound 375-(4-chlorobenzyl)-7-(3-chlorophenyl)-3-(3-hydroxypropyl)-1-methyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

Step 13-(5-(4-chlorobenzyl)-7-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate

To a solution of3-(7-bromo-5-(4-chlorobenzyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (See Compound 34, Step 4, 93 mg, 0.2 mmol),3-chlorophenylboronic acid (62.4 mg, 0.4 mmol), aq. 2M K₃PO₄ (0.4 ml,0.8 mmol) in dioxane (2 mL) was added Pd(dppf)Cl₂ (10 mg, 0.013 mmol).The reaction was degassed with nitrogen (3×), heated at 85° C. (MW) for20 min, cooled to RT, diluted with EA (10 mL) and water (3 mL) thenfiltered. The filtrate was concentrated to a residue which was purifiedby chromatography eluted with PE/EA (2:1) to give3-(5-(4-chlorobenzyl)-7-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (60 mg, 60% yield) as a brown solid. LCMS: MH⁺ 500 andT_(R)=1.905 min.

Step 25-(4-chlorobenzyl)-7-(3-chlorophenyl)-3-(3-hydroxypropyl)-1-methyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

To a solution of3-(5-(4-chlorobenzyl)-7-(3-chlorophenyl)-1-methyl-2,4-dioxo-1H-pyrrolo[3,2-d]pyrimidin-3(2H,4H,5H)-yl)propylacetate (50 mg, 0.1 mmol) in THF (0.5 mL) and water (0.5 mL) was addedLiOH.H₂O (8.4 mg, 0.2 mmol). The reaction was stirred at RT for 30 minthen diluted with EA (5 mL). The organic layer was washed with brine (5mL), dried over Na₂SO₄ and concentrated to a residue which was purifiedby Prep HPLC to give5-(4-chlorobenzyl)-7-(3-chlorophenyl)-3-(3-hydroxypropyl)-1-methyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione(20 mg, 41% yield). ¹H NMR (CDCl₃) δ: 7.39-7.29 (m, 5H), 7.25-7.17 (m,3H), 6.91 (s, 1H), 5.56 (s, 2H), 4.28-4.15 (m, 2H), 3.62 (s, 1H), 3.52(d, J=4.8 Hz, 2H), 3.21 (s, 3H), 1.96-1.82 (m, 2H). LCMS: MH⁺ 458 andT_(R)=2.953 min.

INCORPORATION BY REFERENCE

All publications and patents mentioned herein, are hereby incorporatedby reference in their entirety as if each individual publication orpatent was specifically and individually indicated to be incorporated byreference.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. Such equivalents areintended to be encompassed by the following claims.

The invention claimed is:
 1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein: R¹ is C₂-C₁₀hydroxyalkyl, wherein one or more carbon atoms of the alkyl portion ofthe hydroxyalkyl group is optionally substituted with 1-3 R⁵; R² is H,C₁-C₆ alkyl, C₂-C₆ hydroxyalkyl, cycloalkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, or C₁-C₆ alkoxy; R³ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ alkoxy, C₁-C₆ acyl, C₃-C₁₀ cycloalkyl, halo, hydroxyl,C₆-C₁₂ aryl, 5-14-membered heteroaryl, 3-18-membered heterocycloalkyl,amino, C₁-C₆ alkylamino, C₂-C₁₂ dialkylamino, —C(O)NH—R⁶, —C(O)N—(C₁-C₆alkyl)-R⁶, —NHC(O)—R⁶, —N—(C₁-C₆ alkyl)-C(O)—R⁶, urea, sulfonylurea,nitro, or cyano, wherein each alkyl, alkenyl, alkynyl, alkoxy, acyl,cycloalkyl, aryl, heteroaryl, and heterocycloalkyl represented by R³ isoptionally and independently substituted with 1-4 R⁶; R⁴ is H, C₁-C₆alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ acyl, C₁-C₆ alkoxy, C₄-C₁₀cycloalkyloxy, halo, hydroxyl, alkylthio, sulfonamidyl, C₆-C₁₂ aryl,5-14-membered heteroaryl, C₆-C₁₂ aryl-C₁-C₆ alkyl, 5-14-memberedheteroaryl-C₁-C₆ alkyl, C₆-C₁₂ aryloxy, —O—C₆-C₁₂ aryl-C₁-C₆ alkyl,—O—C₁-C₆ alkyl-C₆-C₁₂ aryl, 5-14-membered heteroaryloxy, 3-18-memberedheterocycloalkyl, amino, C₁-C₆ alkylamino, C₂-C₁₂ dialkylamino,—C(O)NH—R⁷, —C(O)N—(C₁-C₆ alkyl)-R⁷, —N—(C₁-C₆ alkyl)-C(O)—R⁷, urea,sulfonylurea, nitro, or cyano, wherein each alkyl, alkenyl, alkynyl,acyl, alkoxy, cycloalkoxy, alkylthio, aryl, heteroaryl, aryloxy,heteroaryloxy, and heterocycloalkyl represented by R⁴ is optionally andindependently substituted with 1-4 R⁷; R⁵ is H, C₁-C₆ alkyl, C₂-C₆alkenyl, C₂-C₆ alkynyl, C₁-C₆ acyl, C₁-C₆ alkoxy, C₄-C₁₀ cycloalkyloxy,halo, hydroxyl, alkylthio, sulfonamidyl, C₆-C₁₂ aryl, 5-14-memberedheteroaryl, C₆-C₁₂ aryl-C₁-C₆ alkyl, 5-14-membered heteroaryl-C₁-C₆alkyl, C₆-C₁₂ aryloxy, —O—C₆-C₁₂ aryl-C₁-C₆ alkyl, —O—C₁-C₆ alkyl-C₆-C₁₂aryl, 5-14-membered heteroaryloxy, 3-18-membered heterocycloalkyl,amino, C₁-C₆ alkylamino, C₂-C₁₂ dialkylamino, —C(O)NH—R⁷, —C(O)N—(C₁-C₆alkyl)-R⁷, —NHC(O)—R⁷, —N—(C₁-C₆ alkyl)C(O)—R⁷, urea, sulfonylurea,nitro, or cyano, wherein each alkyl, alkenyl, alkynyl, acyl, alkoxy,cycloalkoxy, alkylthio, aryl, heteroaryl, aryloxy, heteroaryloxy, andheterocycloalkyl represented by R⁵ is optionally and independentlysubstituted with 1-4 R⁷; wherein at least two of R³, R⁴ and R⁵ are notH; each R⁶ is independently C₁-C₃ alkyl, halo, hydroxyl, or amino; andeach R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,C₁-C₆ acyl, halo, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, hydroxyl, aryl,heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, cycloalkyloxy, aryloxy,arylalkoxy, heteroaryloxy, amino, C₁-C₆ alkylamino, C₂-C₁₂ dialkylamino,—C(O)NH₂, —C(O)NH—(C₁-C₆ alkyl), —NHC(O)—(C₁-C₆ alkyl), —N—(C₁-C₆alkyl)-C(O)—(C₁-C₆ alkyl), nitro, or cyano.
 2. The compound according toclaim 1, wherein R¹ is an unsubstituted 3-hydroxypropyl; or apharmaceutically acceptable salt thereof.
 3. The compound according toclaim 1, wherein R² is C₁-C₄ alkyl.
 4. The compound according to claim3, wherein R² is methyl.
 5. The compound according to claim 1, whereinR³ is H, C₁-C₄ alkyl, or phenyl, the latter group optionally substitutedwith one or more halogens.
 6. The compound according to claim 5, whereinR³ is methyl or 3-chlorophenyl.
 7. The compound according to claim 1,wherein R⁴ is H, C₁-C₄ alkyl, or phenyl, the latter group substitutedwith one or more halogens or —OCF₃.
 8. The compound according to claim7, wherein R⁴ is 3-chlorophenyl or 3-trifluoromethoxyphenyl.
 9. Thecompound according to claim 1, wherein R⁵ is H, C₁-C₄ alkyl, or benzyl,the latter group substituted with one or more halogens.
 10. The compoundaccording to claim 9, wherein R⁵ is methyl or 4-chlorobenzyl.
 11. Thecompound according to claim 1, wherein: R¹ is 3-hydroxypropyl; R² ismethyl; R³ is H, methyl or 3-chlorophenyl; R⁴ is H, 3-chlorophenyl or3-trifluoromethoxyphenyl; and R⁵ is H, methyl or 4-chlorobenzyl; or apharmaceutically acceptable salt thereof.
 12. The compound according toclaim 1 selected from the group consisting of

or a pharmaceutically acceptable salt thereof.
 13. A pharmaceuticalcomposition comprising at least one compound according to claim 1, or apharmaceutically acceptable salt thereof, in a mixture with apharmaceutically acceptable excipient, diluent or carrier.
 14. A methodof inhibiting TRPC5 comprising contacting a cell with the compoundaccording to claim 1, or a pharmaceutically acceptable salt thereof. 15.A method of treating a TRPC5 mediated disorder in a subject in needthereof, comprising administering to the subject an effective amount ofthe compound according to claim 1, or a pharmaceutically acceptable saltthereof, wherein the TRPC5 mediated disorder is selected from the groupconsisting of: depression, anxiety disorders, Alzheimers disease,Parkinson's disease, Huntingtons disease, ALS, proteinuric kidneydisease and seizure disorder.